- Home
- » Tags
- » Eravacycline
Top View
- WHO Regional Office for Europe Antimicrobial Medicines Consumption (AMC) Network: AMC Data, 2014-2018
- 6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
- AST News Update, Volume 6, Issue 1 – April 2021
- XERAVA (Eravacycline) for Injection, for Intravenous Use • Tooth Discoloration and Enamel Hypoplasia: the Use of XERAVA Initial U.S
- (TP-434) by Broth Microdilution and Disk Diffusion Contact: 53Rd Annual ICAAC M
- 211109Orig1s000
- Eravacycline in Vitro Activity Against European Clinical Isolates Obtained
- Antibiotics Currently in Clinical Development
- Efficacy of Eravacycline in Obese Patients
- Brand Name: Xerava™ Generic Name: Eravacycline Manufacturer1
- A Small Molecule Interacts with Pmac-Derived Hydroperoxide Reductase and Enhances the Activity of Aminoglycosides
- Eravacycline (FDA)
- Global in Vitro Activity of Eravacycline and Comparators Against
- 2019 Antibacterial Agents in Clinical Development
- Tetracycline Antibiotics and Resistance
- Tetracycline-Inactivating Enzymes from Environmental, Human Commensal, and Pathogenic Bacteria Cause Broad-Spectrum Tetracycline Resistance
- Xerava, INN-Eravacycline
- Identification of a Peroxidase Inhibitor That Enhances Kanamycin Activity
- Eravacycline Activity Against Clinical S. Aureus Isolates from China: In
- EUCAST Expert Rules Version 2.0 Was Published on 29 October 2011 and Has Since Been Updated Several Times
- Antibiotics in the Clinical Pipeline in October 2019
- New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
- In Vitro Activity of Eravacycline and Comparators Against Staphylococcus Aureus and Enterococci, Including Methicillin-Resistant And
- In Vitro Activity of Eravacycline and Mechanisms of Resistance In
- 20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: an Update from the Infectious Diseases Society of America
- 510(K) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
- New ATC Codes and New Ddds to Be Included in the 2019 Edition of the ATC/DDD Index Are Also Enclosed
- Xerava (Eravacycline)
- Assessing the Efficacy and Safety of Eravacycline Vs
- In Vitro Activity of Eravacycline and Comparators Against Acinetobacter
- BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
- Antibiotics Currently in Clinical Development Note: This Data Visualization Was Updated in December 2016 with New Data
- Methods Abstract Results Assessment of Eravacycline Against a Recent
- Antibiotic Stewardship in Long-Term Care: the Path of Least Resistance Indiana September 13, 2016
- Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections
- Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
- Antimicrobial Dosing Recommendations for Adult Patients1
- Restricted Antimicrobials Requiring Ast Approval in Patients on Adult Services
- ECDC/EFSA/EMA Third Joint Report on the Integrated Analysis of the Consumption of Antimicrobial Agents and Occurrence of Antimic
- In Vitro Activity of Eravacycline and Comparators Against Staphylococcus Aureus and Enterococci, Including Methicillin-Resistant And
- Activity of Eravacycline Against Anaerobic Bacteria from Europe Collected in 2013-14 IHMA Europe Sarl Phone: +44 (0) 1279 724929 I
- Eravacycline, a Newly Approved Fluorocycline
- Antibiotics in the Clinical Pipeline in 2013
- In Vitro Activity of Eravacycline and Comparators Against Acinetobacter Baumannii, Stenotrophomonas Maltophilia And